Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14491320 | 0.92 | NR1I2 (0.43) | NR1I2PPARGPPARDOGAGPR119 | |
| SCHEMBL10327470 | 0.89 | TLR7 (0.38) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327522 | 0.89 | PPARG (0.37) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327517 | 0.89 | TLR7 (0.38) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL1562365 | 0.89 | F2RL3 (0.39) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327459 | 0.88 | TLR7 (0.39) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327376 | 0.88 | PPARG (0.38) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327585 | 0.87 | PPARG (0.38) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL10327532 | 0.86 | RAB9A (0.37) | NR1I2PPARGPPARDTLR7TLR9 | |
| SCHEMBL12711510 | 0.84 | TLR7 (0.39) | NR1I2TLR7TLR9F2RL3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | NR1I2 1155/4885PPARG 3081/4885PPARD 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.